Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical

As part of the ASSET innovation partnership led by Diamyd Medical, the Leading Healthcare Foundation organizes a conference on November 26, 2024, in Stockholm, Sweden, on the future of Type 1 Diabetes screening and treatment. The conference is co-sponsored by Sanofi.

The event gathers key stakeholders, including patient organizations, healthcare professionals, researchers, and regulators, to explore the practical implementation of precision and preventive medicine in Type 1 Diabetes care.

The conference will feature a keynote lecture by Prof. Chantal Mathieu, President of the European Association for the Study of Diabetes (EASD), and leading expert in diabetes care, who will discuss ongoing screening initiatives and guidelines in Europe. 

Additionally, two panel discussions will bring together patient and professional organizations, clinicians, regulators and policymakers. These discussions will center on the ethical, regulatory and policy requirements needed to integrate new screening technologies and innovative precision medicine therapies into the healthcare system.

“Together with our ASSET partners and Sanofi, we are excited to expand the conversation on how early diagnosis and innovative approaches in precision medicine can transform Type 1 Diabetes care,” says Ulf Hannelius, CEO of Diamyd Medical. “By working together, we can drive the changes needed to make early diagnosis and precision treatment for Type 1 Diabetes a reality.”

For more details and to register for the event, please visit https://leadinghealthcare.se/kalendern/framtidens-screening-konferens/.

About ASSET

The innovation milieu ASSET (AI for Sustainable Prevention of Autoimmunity in the Society) is an industry-healthcare partnership including Mainly AI, Lund University, Sahlgrenska University Hospital, Örebro University Hospital, The Swedish National Diabetes Register, Leading Health Care Foundation and Diamyd Medical, project coordinator. The project started in September 2021, has a duration of five years, and is financed by the Swedish innovation agency VINNOVA.

ASSET has three main goals: Predict, Prevent and Implement.

Predict:  evaluate new algorithms based on Artificial Intelligence (AI) to be able to assess the individual risk of developing Type 1 Diabetes (T1D), and the likelihood of responding to different treatments. Data from cohort studies such as TEDDY (The Environmental Determinants of Diabetes in the Young), from Diamyd Medical's clinical trials with Diamyd^® and from sources such as the National Diabetes Registry will constitute the initial training dataset for the algorithm. T1D will form the pilot project for the program, but the goal is extending the functionality to other indications including other autoimmune diseases that are strongly linked to T1D such as celiac disease (gluten intolerance) and autoimmune thyroiditis (inflammatory disease of the thyroid gland).

Prevent: ASSET aims to be a test-bed for clinical development, with a pilot trial ongoing testing a precision medicine approach to early stage T1D.

Implement: ASSET will study organizational, economic, and legal prerequisites and consequences of applying the approach as a tool for precision health in the Swedish health care system. The goal is to proactively manage obstacles that can slow down the implementation and spread of the innovations in the healthcare system. 

Website: https://www.asset.healthcare.se

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd^® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company’s prospective European Phase IIb trial, where Diamyd^® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical also develops the GABA-based investigational drug Remygen^® as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.